Reactions 1680, p50 - 2 Dec 2017 Virological failure and acquired multi-antiviral resistance to HIV-1C infection: 26 case reports In a prospective cohort study of 320 patients, 15 women and 11 men aged between 25–51 years were described, who developed virological failure and acquired multi-antiviral resistance to antivirals during treatment of HIV-1C infection [routes and dosages not stated]. The patients, who had a history of HIV-1C infection, started receiving treatment with lamivudine, stavudine and nevirapine (9 patients), lamivudine, stavudine and efavirenz (1 patient), lamivudine, zidovudine and nevirapine (12 patients) and lamivudine, zidovudine and efavirenz (4 patients). After 5–8 years of antiviral treatments, the patients developed virological failure and acquired multi-antiviral drug resistance mutations, which were confirmed by genotypic susceptibility test [outcomes not stated]. Author comment: "This study describes a decade virological outcomes and measures the incidence of virological failure and acquired drug resistance mutations in Ethiopian HIV-1C infected adults at 4 time points from the Horn of Africa." Mulu A, et al. Upward trends of acquired drug resistances in Ethiopian HIV-1C isolates: A decade longitudinal study. PLOS One 12: e0186619, No. 10, Oct 2017. Available from: URL: http://doi.org/10.1371/journal.pone.0186619 - Ethiopia 803284108 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera